Skip to content

The effect of short term Topiramate treatment on insulin secretion, glucose and lipid metabolism in obese women

The effect of short term Topiramate treatment on insulin secretion, glucose and lipid metabolism in obese women

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON28677
Enrollment
13
Registered
2008-04-21
Start date
2008-05-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus Obesity Insulin resistance

Interventions

Topiramate: first week 25 mg od (evening) second week 25 mg bid third and fourth week 25 mg od (morning) + 50 mg od (evening)

Sponsors

TI pharma
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Female volunteers 2. Age > 18 years and 27 kg/m2 and < 44 kg/m2 4. Fasting serum glucose (FSG) 6.1-7 mmol/L

Exclusion criteria

Exclusion criteria: 1. FSG >7 mmol/L 2. Psychiatric disorders and/or use of antipsychotic or antidepressants drugs at present or in the past. 3. Any significant chronic disease 4. Any significant abnormal laboratory results found during the medical screening procedure 5. Renal, hepatic or endocrine disease (including DM) 6. Use of medication known to influence glucose and/or FFA metabolism 7. Premenopausal women who do not use oral contraceptives or intrauterine device (IUD) 8. Recent weight changes or attempts to loose weight (> 3 kg weight gain or loss, within the last 3 months) 9. Difficulties to insert an intravenous catheter 10. Smoking 11. Severe claustrophobia (ventilated hood) 12. Recent blood donation (within the last 3 months) 13. Recent participation in other research projects (within the last 3 months), participation in 2 or more projects in one year

Design outcomes

Primary

MeasureTime frame
• Glucose metabolism: Endogenous glucose production, Ra and Rd of glucose by infusion of [6,6-2H2]glucose two-step hyperinsulinaemic euglycaemic clamp • ß-cell sensitivity: Early and late response of insulin secretion (hyperglycemic clamp)

Secondary

MeasureTime frame
• Anthropometric: Weight, height, waist and hip circumference, Bioelectrical impedance analysis • Lipid metabolism: Ra glycerol by infusion of [2H5]glycerol Indirect calorimetry:resting energy expenditure and RQ, glucose and lipid oxidation rates • Plasma concentrations: Total cholesterol, HDL-C, LDL-C, Triglycerides, Glucose, insulin, glucagon, free fatty acid, • Actimety: Resting energy expenditure, diet induced thermogenesis, active energy expenditure and total energy expenditure. • Diary: Calorie intake, Physical activity

Contacts

Public ContactM. Snel

LUMC, afdeling AIG (C4-70)

m.snel@lumc.nl+31 (0)71 5264839

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)